Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-GU: Rivaroxaban for VTE Prevention in GU Cancer
NCT05920343Phase 3Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Feasibility of enrollment. Started Nov 2024; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05920343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920343.